Published in BMC Gastroenterol on May 05, 2014
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci (2014) 1.63
Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. AIDS Patient Care STDS (2015) 0.83
Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. J Dermatol Case Rep (2014) 0.79
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Braz J Med Biol Res (2016) 0.77
Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One (2016) 0.77
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLoS One (2015) 0.77
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study. Medicine (Baltimore) (2015) 0.75
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol (2015) 0.75
Effectiveness research in the evolving HCV landscape. Dig Dis Sci (2014) 0.75
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics (Sao Paulo) (2017) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol (2013) 1.68
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol (2010) 1.51
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol (2012) 1.17
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther (2013) 1.16
"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus. Hepatology (2011) 0.81
Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med (2011) 8.55
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med (2014) 4.57
Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol (2012) 4.04
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl (2006) 3.73
FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol (2012) 3.57
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol (2007) 2.77
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS (2008) 2.66
Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest (2012) 2.55
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother (2008) 2.52
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS (2002) 2.40
Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology (2014) 2.39
HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet (2004) 2.36
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis (2009) 2.03
Reduced expression of Blimp-1 in memory B cells in patients with HIV-1 infection suggests distinct roles of this molecule for B and T cell regulation. AIDS (2014) 1.99
Primary biliary "cirrhosis": time to replace a misnomer. Hepatology (2014) 1.98
Effectiveness and safety of minilaparoscopy-guided spleen biopsy: a retrospective series of 57 cases. Surg Endosc (2012) 1.96
Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol (2010) 1.86
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol (2010) 1.80
Immune tolerance: what is unique about the liver. J Autoimmun (2009) 1.79
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology (2008) 1.68
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol (2010) 1.61
The indications for liver biopsy. Dtsch Arztebl Int (2012) 1.60
Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol (2006) 1.59
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Pancreas and liver injury are associated in individuals with increased alcohol consumption. Clin Gastroenterol Hepatol (2009) 1.56
Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55
Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2005) 1.54
Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest (2002) 1.50
Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation (2004) 1.45
Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol (2006) 1.45
Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest (2008) 1.44
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med (2012) 1.43
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis (2006) 1.42
Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol (2005) 1.42
Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis. AIDS (2002) 1.38
Viruses acquired abroad: what does the primary care physician need to know? Dtsch Arztebl Int (2012) 1.38
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol (2011) 1.36
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol (2012) 1.29
Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J (2013) 1.26
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS (2008) 1.25
Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J (2012) 1.25
Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer (2013) 1.23
Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. J Clin Virol (2010) 1.23
TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. Int Immunol (2004) 1.22
PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene (2003) 1.21
Living donor liver transplantation. J Hepatol (2003) 1.18
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology (2010) 1.18
Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology (2011) 1.18
Absence of erythrocyte sequestration and lack of multicopy gene family expression in Plasmodium falciparum from a splenectomized malaria patient. PLoS One (2009) 1.18
Coexpression of TGF-beta1 and IL-10 enables regulatory T cells to completely suppress airway hyperreactivity. J Immunol (2008) 1.17
Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology (2011) 1.17
Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr (2008) 1.15
MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology (2003) 1.15
Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med (2016) 1.15
Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One (2010) 1.15
Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology (2012) 1.15
P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg. PLoS One (2008) 1.14
IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. J Clin Invest (2010) 1.14
Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology (2004) 1.13
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos (2008) 1.12
Evolution of donor morbidity in living related liver transplantation: a single-center analysis of 165 cases. Ann Surg (2004) 1.12
Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology (2013) 1.11
Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? J Infect Dis (2013) 1.10
Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology (2011) 1.09
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR. Trop Med Int Health (2003) 1.07
Phenotypic alterations of regulatory T cells in autoimmune hepatitis: causal or associated with treatment and remission? Hepatology (2015) 1.06
Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells. J Immunol (2009) 1.05
Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol (2006) 1.05
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol (2012) 1.05
Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol (2008) 1.05
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther (2013) 1.04
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol (2004) 1.04
Laparoscopic Heller myotomy versus endoscopic balloon dilatation for the treatment of achalasia: a network meta-analysis. Ann Surg (2013) 1.04
Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol (2003) 1.04
Murine liver antigen presenting cells control suppressor activity of CD4+CD25+ regulatory T cells. Hepatology (2005) 1.03
Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transpl (2003) 1.03
Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology (2003) 1.02
The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis (2007) 1.02
Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology (2005) 1.02
Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos. Trop Med Int Health (2003) 1.01
Mini-laparoscopically guided percutaneous gastrostomy and jejunostomy. Gastrointest Endosc (2003) 1.01
Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J Immunol (2006) 1.01